269 related articles for article (PubMed ID: 10502307)
1. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
Romero DV; Partilla JS; Zheng QX; Heyliger SO; Ni Q; Rice KC; Lai J; Rothman RB
Synapse; 1999 Nov; 34(2):83-94. PubMed ID: 10502307
[TBL] [Abstract][Full Text] [Related]
2. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
Heyliger SO; Jackson C; Rice KC; Rothman RB
Synapse; 1999 Dec; 34(4):256-65. PubMed ID: 10529720
[TBL] [Abstract][Full Text] [Related]
3. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
4. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
Gengo PJ; Pettit HO; O'Neill SJ; Wei K; McNutt R; Bishop MJ; Chang KJ
J Pharmacol Exp Ther; 2003 Dec; 307(3):1221-6. PubMed ID: 14534368
[TBL] [Abstract][Full Text] [Related]
5. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
6. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
7. Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.
Alt A; Clark MJ; Woods JH; Traynor JR
Br J Pharmacol; 2002 Jan; 135(1):217-25. PubMed ID: 11786497
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF
Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410
[TBL] [Abstract][Full Text] [Related]
9. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
10. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
[TBL] [Abstract][Full Text] [Related]
11. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.
Schoffelmeer AN; Hogenboom F; Mulder AH
Br J Pharmacol; 1997 Oct; 122(3):520-4. PubMed ID: 9351509
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of adenylyl cyclase activity by mu and delta opioids in rat caudate putamen and nucleus accumbens.
Izenwasser S; Búzás B; Cox BM
J Pharmacol Exp Ther; 1993 Oct; 267(1):145-52. PubMed ID: 7901389
[TBL] [Abstract][Full Text] [Related]
13. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of naltriben as a ligand for opioid mu and kappa receptors in rat cerebral cortex.
Kim KW; Son Y; Shin BS; Cho KP
Life Sci; 2001 Feb; 68(11):1305-15. PubMed ID: 11233997
[TBL] [Abstract][Full Text] [Related]
15. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.
Selley DE; Sim LJ; Xiao R; Liu Q; Childers SR
Mol Pharmacol; 1997 Jan; 51(1):87-96. PubMed ID: 9016350
[TBL] [Abstract][Full Text] [Related]
16. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling.
Hou Y; Tan Y; Belcheva MM; Clark AL; Zahm DS; Coscia CJ
Brain Res Dev Brain Res; 2004 Jul; 151(1-2):149-57. PubMed ID: 15246701
[TBL] [Abstract][Full Text] [Related]
18. Autoradiographic distribution of mu-, delta- and kappa 1-opioid stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in human frontal cortex and cerebellum.
Platzer S; Winkler A; Schadrack J; Dworzak D; Tölle TR; Zieglgänsberger W; Spanagel R
Neurosci Lett; 2000 Apr; 283(3):213-6. PubMed ID: 10754225
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
20. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro.
Feng J; Kendig JJ
Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
